Labetalol Synchrony (Labetalol Hydrochloride)

Labetalol Hydrochloride combines non‑selective β‑adrenergic blockade with selective α1‑adrenergic blockade. The β‑blockade reduces heart rate and contractility, while the α1‑blockade causes vasodilation. Together these actions lower cardiac output and peripheral resistance, leading to a reduction in arterial blood pressure.

The dose of Labetalol Synchrony is individualized and determined by the prescribing clinician based on the patient’s condition, severity of hypertension, and response to therapy. Specific dosing regimens are not provided here and should follow the prescriber’s instructions.

Labetalol Synchrony may be used in severe hypertension during pregnancy, such as pre‑eclampsia, under close medical supervision. Data on safety during breastfeeding are limited; therefore, the benefits and risks should be carefully weighed by the healthcare provider before use.

To order Labetalol Synchrony, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain where applicable) and import documentation.

Labetalol’s unique combination of β‑ and α1‑blockade distinguishes it from pure β‑blockers or vasodilators. This dual action provides effective blood pressure reduction with less reflex tachycardia, making it useful in situations where rapid control is needed, such as hypertensive emergencies, whereas many other agents act through a single mechanism.

Labetalol Synchrony should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging to maintain stability and prevent contamination.

Labetalol Synchrony is administered intravenously by a healthcare professional. It is typically given as a continuous infusion or intermittent IV bolus, depending on the clinical scenario and the prescriber’s protocol.

Serious risks include severe hypotension, marked bradycardia, hepatic dysfunction, and bronchospasm, especially in patients with underlying asthma or chronic obstructive pulmonary disease. Prompt monitoring of blood pressure, heart rate and liver enzymes is essential during therapy.

Labetalol Synchrony is contraindicated in patients with known hypersensitivity to labetalol or any component of the formulation, in those with severe bradycardia, second‑ or third‑degree heart block without a pacemaker, and in patients with uncompensated heart failure or acute bronchospasm.